Menu
← Oncology Approval Tracker
FDA DECISION ·
Lutathera
lutetium Lu 177 dotatate · Advanced Accelerator Applications USA (Novartis)
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut and hindgut tumors.
LAMPGEN ANALYSIS
Why it matters
The label expanded a targeted radioligand option to adolescents with rare neuroendocrine tumors.
What research teams should watch
Coordinate receptor imaging, amino acid infusion, radiation precautions and family education across nuclear medicine and pediatric oncology.
PRIMARY RECORDS